
About Eliem Therapeutics
Eliem Therapeutics is a Healthcare company based in Boston (United States) founded in 2018 by Valerie Morisset and Andrew Levin. It develops antibody-based treatments for autoimmune and inflammatory disorders. It operates on a B2B model. Eliem Therapeutics has raised $171.3 million across 5 funding rounds from investors including RA Capital, ICG and LifeArc. The company has 30 employees. Eliem Therapeutics has completed 1 acquisition, including Tenet Medicines. Eliem Therapeutics offers products and services including Budoprutug. Its focus areas include Biopharmaceuticals, Autoimmune Diseases, Inflammatory Therapeutics and Biotech. Its legal entity is Eliem Therapeutics, Inc. Its competitors include Flexion Therapeutics, Cara Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.
Company details
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on creating therapeutics for autoimmune-driven inflammatory diseases. They advance treatments like budoprutug, an anti-CD19 antibody that depletes B cells to reduce autoantibodies. Operating from locations in the US and UK, they conduct clinical trials for conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, collaborating with experts in biotechnology.
- Headquarters Boston, United States
- Employees 30
- Founders Valerie Morisset, Andrew Levin
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website eliemtx.com
- Social LinkedIn
- Legal Name Eliem Therapeutics, Inc.
- Total Equity Funding$171.3M (USD)
in 5 rounds
- Latest Funding Round$60M (USD), Series C
May 2021
- InvestorsRA Capital
& 5 more
- Employee Count30
- Investments & Acquisitions
Products & Services of Eliem Therapeutics
Eliem Therapeutics offers a comprehensive portfolio of products and services, including Budoprutug.
Anti-CD19 antibody to deplete B cells and reduce autoantibodies.
Funding Insights of Eliem Therapeutics
Eliem Therapeutics has successfully raised a total of $171.3M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $171.3M
- Total Rounds 5
- Last Round Series C β $60M
- First Round $16.3M
(Feb 2019)
- Investors Count 6
All 5 funding rounds of Eliem Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $60M | Series C | β | β | β |
| Mar 2021 | $80M | Series C | β | RA Capital Management, ICG | |
| Oct 2020 | $5M | Series B | β | β | β |
| Oct 2019 | $10M | Series B | β | β | β |
| Feb 2019 | $16.3M | Series B | β | β | β |
6 investors in total: 6 institutional.
Investors in Eliem Therapeutics
Eliem Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, ICG and LifeArc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
ICG is recognized as a global alternative asset manager. | 1989 | icgam.com | London, United Kingdom | |
| acornbioventures.com | ||||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Access Biotechnology is engaged in investing in transformative biopharma therapies. | 1986 | accessbio-tech.com | New York, United States | |
Offers secure online access to investment materials for authorized users only. | 2006 | samlyncapital.com | New York, United States | |
Medical research and treatments are supported by the community foundation. | 1992 | lifearc.org | London, United Kingdom |
Investor details for Eliem Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eliem Therapeutics
12 people are tracked at Eliem Therapeutics (7 in leadership, 4 in board & advisors, 1 in team); the tracked headcount is 30.
| Name | Role | Group |
|---|---|---|
Valerie Morisset | Co-Founder | Leadership |
Andrew Levin | Co-Founder | Leadership |
Nicholas Nebbeling | Controller/director Of Accounting | Leadership |
Jo Palmer-Phillips | Chief Development Officer | Leadership |
Bob Azelby | President & CEO | Leadership |
Susan Franks | SVP & Head of Regulatory Affairs | Leadership |
Emily Pimblett, CPA | Vice President Of Accounting | Leadership |
Simon Tate | Director | Board & advisors |
Judith Dunn | Director | Board & advisors |
Liam Ratcliffe | Director | Board & advisors |
Adam Rosenberg | Director | Board & advisors |
Cheryl T. | Staff Accountant | Team |
Complete people profiles for Eliem Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eliem Therapeutics
Eliem Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tenet Medicines.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for autoimmune-driven inflammatory diseases are developed. | Scotch Plains, United States | 2023 | Apr 2024 | β’β’β’β’ |
Complete acquisition details for Eliem Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Eliem Therapeutics
5 dated milestones of Eliem Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Eliem Therapeutics is founded.
- Funding First funding round of $16.3M.
- Funding Latest funding round, Series C, of $60.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Tenet Medicines.
Competitors of Eliem Therapeutics
Eliem Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Zogenix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. |
Detailed competitors of Eliem Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Eliem Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eliem Therapeutics
Complete news archive for Eliem Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eliem Therapeutics
Eliem Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Eliem Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Eliem Therapeutics is a funded company, having raised a total of $171.3M across 5 funding rounds to date. The company's 1st funding round was a Series B of $16.3M, raised on Feb 2019.
Eliem Therapeutics has 30 employees.
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on creating therapeutics for autoimmune-driven inflammatory diseases. They advance treatments like budoprutug, an anti-CD19 antibody that depletes B cells to reduce autoantibodies. Operating from locations in the US and UK, they conduct clinical trials for conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, collaborating with experts in biotechnology.
Eliem Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Zogenix.
Eliem Therapeutics offers Budoprutug.
Eliem Therapeutics has made 1 acquisition, including Tenet Medicines.
Eliem Therapeutics has 6 investors. Key investors include RA Capital, ICG, LifeArc, Access Biotechnology, and Samlyn Capital.
Eliem Therapeutics operates through Eliem Therapeutics, Inc..
